Athersys News - ATHX

Company Name	Stock Ticker Symbol	Market	Type
Athersys Inc	ATHX	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.00	0.00%	0.1018	20:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
				0.1018

more quote information »

Recent News

Date	Time	Source	Heading
1/08/2024	07:31	EDGAR2	Form 8-K - Current report
12/22/2023	17:09	EDGAR2	Form 8-K - Current report
12/21/2023	11:37	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/16/2023	08:35	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/18/2023	08:00	EDGAR2	Form 8-K - Current report
10/16/2023	16:52	BW	Athersys Extends Near Term Liquidity with Proceeds from..
10/12/2023	09:28	EDGAR2	Form 8-K - Current report
10/11/2023	09:27	EDGAR2	Form 8-K - Current report
10/10/2023	08:30	BW	Athersys Reports Interim Analysis Results of MASTERS-2..
10/06/2023	17:34	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/06/2023	17:28	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/03/2023	16:41	EDGAR2	Form 8-K - Current report
10/03/2023	16:30	BW	Athersys Licenses its Animal Health Assets to Ardent Animal..
10/02/2023	17:05	EDGAR2	Form 8-K - Current report
10/02/2023	17:04	BW	Athersys Director Jane Wasman Appointed Board Chair
9/25/2023	16:36	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
9/22/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
9/19/2023	12:28	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/18/2023	21:35	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
9/18/2023	21:04	EDGAR2	Form 8-K - Current report
9/14/2023	11:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/14/2023	10:41	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
9/13/2023	17:13	EDGAR2	Form S-3 - Registration statement under Securities Act of..
9/11/2023	08:46	EDGAR2	Form 8-K - Current report
9/06/2023	14:45	BW	Grant Awarded to Newcastle University to Research Athersys’..
8/21/2023	14:36	EDGAR2	Form 424B4 - Prospectus [Rule 424(b)(4)]
8/18/2023	10:14	EDGAR2	Form 8-K - Current report
8/17/2023	21:30	BW	Athersys, Inc. Announces Pricing of $3.5 Million Public..
8/17/2023	16:15	EDGAR2	Form DEF 14A - Other definitive proxy statements
8/16/2023	17:05	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/16/2023	17:01	BW	Athersys Reports Second Quarter 2023 Financial Results and..
8/11/2023	08:19	EDGAR2	Form 8-K - Current report
8/11/2023	08:00	BW	Athersys Appoints Neema Mayhugh, PhD to its Board of..
8/10/2023	17:03	EDGAR2	Form 8-K - Current report
8/08/2023	08:02	EDGAR2	Form 8-K - Current report
8/07/2023	17:02	EDGAR2	Form S-1/A - General form for registration of securities..
7/31/2023	13:38	BW	Athersys to Host Business Update Conference Call on August..
7/31/2023	08:01	EDGAR2	Form 8-K - Current report
7/26/2023	09:19	EDGAR2	Form S-1/A - General form for registration of securities..
7/14/2023	16:31	EDGAR2	Form S-1 - General form for registration of securities under..
7/14/2023	16:16	EDGAR2	Form 8-K/A - Current report: [Amend]
7/06/2023	09:53	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/06/2023	09:51	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/05/2023	14:04	EDGAR2	Form 8-K - Current report
6/01/2023	16:40	BW	Patient Enrollment Begins in Third and Final Cohort of the..
5/23/2023	08:30	BW	Athersys Restructures Debt with Supplier
5/18/2023	09:58	BW	Athersys Reports First Quarter 2023 Financial Results and..
5/08/2023	09:49	BW	Athersys to Participate in Three Upcoming Conferences
5/01/2023	08:30	BW	Athersys to Participate in The Cellular Therapies and..